Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(4):443–451. doi: 10.1054/bjoc.2000.1599

The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients

A Gochi 1, K Orita 1, S Fuchimoto 1, N Tanaka 1, N Ogawa 1
PMCID: PMC2363772  PMID: 11207036

Abstract

To investigate, by a multi-institutional randomized trial, the prognostic significance of the augmentation of tumour-infiltrating lymphocytes (TILs) by preoperative intratumoral injection of OK-432 (OK-432 it), a bacterial biological response modifier, in patients with gastric cancer. The 10-year survival and disease-free survival were examined and analysis of the factors showing survival benefit was performed. 370 patients who had undergone curative resection of gastric cancer were enrolled in this study and followed up for 10 years postoperatively. Patients were randomized into either an OK-432 it group or a control group. Ten Klinishe Einheit (KE) of OK-432 was endoscopically injected at 1 to 2 weeks before the operation in the OK-432 it group. Both groups received the same adjuvant chemoimmunotherapy consisting of a bolus injection of mitomycin C (0.4 mg kg−1i.v.) and administration of tegafur and OK-432 from postoperative day 14 up to 1 year later. Tegafur (600 mg day−1) was given orally and OK-432 (5 KE/2 weeks) was injected intradermally for a maintenance therapy. The TILs grades in resected tumour specimens and presence of metastasis and metastatic pattern in dissected lymph nodes were examined. Multivariate analysis was performed to determine the efficacy of OK-432 it on prognostic factors. All patients were followed up for 10 years. The overall 5- and 10-year survival rates and disease-free survival rates of the OK-432 it group were not significantly higher than those of the control group. However, OK-432 it significantly increased the 5- and 10-year survival rates of patients with stage IIIA + IIIB, moderate lymph node metastasis (pN2), and positive TILs. OK-432 it was most effective at prolonging the survival of patients who had both positive TILs and lymph node metastasis. The OK-432 it group with positive TILs showed a significant decrease in metastatic lymph node frequency and in the number of lymph node micro- metastatic foci when compared to the control group. This study showed that only one time preoperative OK-432 it, particularly when it triggers TILs, is effective for reduction of regional lymph node metastasis. OK-432 it probably acts partly by eliminating micro-metastatic foci in lymph nodes. Preoperative intratumoral injection of OK-432 is technically very easy and has no serious adverse effects, so it is a promising form of neoadjuvant immunotherapy for advanced gastric cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: intratumoral injection, OK-432 (picibanil), medical lymphadenectomy, preoperative immunotherapy

Full Text

The Full Text of this article is available as a PDF (311.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arinaga S., Karimine N., Takamuku K., Nanbara S., Inoue H., Abe R., Watanabe D., Matsuoka H., Ueo H., Akiyoshi T. A trial of adjuvant chemoimmunotherapy with mitomycin C and OK-432 for stage III gastric carcinoma. J Surg Oncol. 1992 Jul;50(3):187–189. doi: 10.1002/jso.2930500312. [DOI] [PubMed] [Google Scholar]
  2. BLACK M. M., OPLER S. R., SPEER F. D. Structural representations of tumor-host relationships in gastric carcinoma. Surg Gynecol Obstet. 1956 May;102(5):599–603. [PubMed] [Google Scholar]
  3. Frost P., Ng C. P., Belldegrun A., Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol. 1997 Aug 25;180(1):70–83. doi: 10.1006/cimm.1997.1169. [DOI] [PubMed] [Google Scholar]
  4. Gotoh K., Gouchi A., Akura Y., Tanaka N., Orita K. Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers. Int J Immunopharmacol. 1991;13(5):485–492. doi: 10.1016/0192-0561(91)90067-h. [DOI] [PubMed] [Google Scholar]
  5. Howson C. P., Hiyama T., Wynder E. L. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1–27. doi: 10.1093/oxfordjournals.epirev.a036288. [DOI] [PubMed] [Google Scholar]
  6. Ikeda H., Sato N., Matsuura A., Sasaki A., Takahashi S., Kozutsumi D., Kobata T., Okumura K., Wada Y., Hirata K. Clonal dominance of human autologous cytotoxic T lymphocytes against gastric carcinoma: molecular stability of the CDR3 structure of the TCR alphabeta gene. Int Immunol. 1996 Jan;8(1):75–82. doi: 10.1093/intimm/8.1.75. [DOI] [PubMed] [Google Scholar]
  7. Inokuchi K., Hattori T., Taguchi T., Abe O., Ogawa N. Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer. 1984 Jun 1;53(11):2393–2397. doi: 10.1002/1097-0142(19840601)53:11<2393::aid-cncr2820531104>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  8. Ioannides C. G., Fisk B., Jerome K. R., Irimura T., Wharton J. T., Finn O. J. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol. 1993 Oct 1;151(7):3693–3703. [PubMed] [Google Scholar]
  9. Ishii Y., Yamaoka H., Toh K., Kikuchi K. Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Gan. 1976 Feb;67(1):115–119. [PubMed] [Google Scholar]
  10. Itoh K., Tilden A. B., Balch C. M. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res. 1986 Jun;46(6):3011–3017. [PubMed] [Google Scholar]
  11. Kataoka K., Naomoto Y., Orita K. In vitro induction of perforin mRNA and cytotoxic activities in human splenocytes by the streptococcal preparation, OK-432. Jpn J Clin Oncol. 1991 Oct;21(5):330–333. [PubMed] [Google Scholar]
  12. Kägi D., Vignaux F., Ledermann B., Bürki K., Depraetere V., Nagata S., Hengartner H., Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994 Jul 22;265(5171):528–530. doi: 10.1126/science.7518614. [DOI] [PubMed] [Google Scholar]
  13. Liu C. C., Walsh C. M., Young J. D. Perforin: structure and function. Immunol Today. 1995 Apr;16(4):194–201. doi: 10.1016/0167-5699(95)80121-9. [DOI] [PubMed] [Google Scholar]
  14. Lopez C. B., Rao T. D., Feiner H., Shapiro R., Marks J. R., Frey A. B. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell Immunol. 1998 Dec 15;190(2):141–155. doi: 10.1006/cimm.1998.1390. [DOI] [PubMed] [Google Scholar]
  15. Lowin B., Hahne M., Mattmann C., Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994 Aug 25;370(6491):650–652. doi: 10.1038/370650a0. [DOI] [PubMed] [Google Scholar]
  16. Maehara Y., Moriguchi S., Sakaguchi Y., Emi Y., Kohnoe S., Tsujitani S., Sugimachi K. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol. 1990 Nov;45(3):169–172. doi: 10.1002/jso.2930450307. [DOI] [PubMed] [Google Scholar]
  17. Maguire H. C., Jr, Ketcha K. A., Lattime E. C. Neutralizing anti-IL-10 antibody upregulates the induction and elicitation of contact hypersensitivity. J Interferon Cytokine Res. 1997 Dec;17(12):763–768. doi: 10.1089/jir.1997.17.763. [DOI] [PubMed] [Google Scholar]
  18. Nakazato H., Koike A., Saji S., Ogawa N., Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994 May 7;343(8906):1122–1126. doi: 10.1016/s0140-6736(94)90233-x. [DOI] [PubMed] [Google Scholar]
  19. Niimoto M., Hattori T., Ito I., Tamada R., Inokuchi K., Orita K., Furue H., Ogawa N., Toda T., Furusawa M. Levamisole in postoperative adjuvant immunochemotherapy for gastric cancer. A randomized controlled study of the MMC + Tegafur regimen with or without levamisole. Report I. Cancer Immunol Immunother. 1984;18(1):13–18. doi: 10.1007/BF00205393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Noguchi M., Miyazaki I. Prognostic significance and surgical management of lymph node metastasis in gastric cancer. Br J Surg. 1996 Feb;83(2):156–161. [PubMed] [Google Scholar]
  21. Saito M., Ebina T., Koi M., Yamaguchi T., Kawade Y., Ishida N. Induction of interferon-gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol. 1982 Mar 15;68(1):187–192. doi: 10.1016/0008-8749(82)90102-2. [DOI] [PubMed] [Google Scholar]
  22. Sato M., Harada K., Yoshida H., Yura Y., Azuma M., Iga H., Bando T., Kawamata H., Takegawa Y. Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis. 1997;2(2):227–238. doi: 10.1023/a:1026428918301. [DOI] [PubMed] [Google Scholar]
  23. Schendel D. J., Gansbacher B., Oberneder R., Kriegmair M., Hofstetter A., Riethmüller G., Segurado O. G. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol. 1993 Oct 15;151(8):4209–4220. [PubMed] [Google Scholar]
  24. Siewert J. R., Böttcher K., Roder J. D., Busch R., Hermanek P., Meyer H. J. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993 Aug;80(8):1015–1018. doi: 10.1002/bjs.1800800829. [DOI] [PubMed] [Google Scholar]
  25. Slovin S. F., Lackman R. D., Ferrone S., Kiely P. E., Mastrangelo M. J. Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol. 1986 Nov 1;137(9):3042–3048. [PubMed] [Google Scholar]
  26. Tanaka N., Gouchi A., Ohara T., Mannami T., Konaga E., Fuchimoto S., Okamura S., Sato K., Orita K. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Cancer. 1994 Dec 15;74(12):3097–3103. doi: 10.1002/1097-0142(19941215)74:12<3097::aid-cncr2820741206>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  27. Toda K., Shiraishi T., Hirotsu T., Fukuyama K., Mineta T., Kawaguchi S., Tabuchi K. The cytocidal activity of OK-432-activated mononuclear cells against human glioma cells is partly mediated through the Fas ligand/Fas system. Jpn J Cancer Res. 1996 Sep;87(9):972–976. doi: 10.1111/j.1349-7006.1996.tb02128.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Topalian S. L., Solomon D., Rosenberg S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989 May 15;142(10):3714–3725. [PubMed] [Google Scholar]
  29. Uchida A., Micksche M. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. J Natl Cancer Inst. 1983 Oct;71(4):673–680. [PubMed] [Google Scholar]
  30. Watanabe Y., Iwa T. Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer. 1984 Jan 15;53(2):248–253. doi: 10.1002/1097-0142(19840115)53:2<248::aid-cncr2820530211>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  31. Yamamoto A., Nagamuta M., Usami H., Sugawara Y., Watanabe N., Niitsu Y., Urushizaki I. Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacology. 1986 Apr;11(2):79–86. doi: 10.1016/0162-3109(86)90027-5. [DOI] [PubMed] [Google Scholar]
  32. Yang K. D., Stone R. M., Lee C. S., Chao T. Y., Cheng S. N., Shaio M. F. Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother. 1992;35(4):277–282. doi: 10.1007/BF01789335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Yasumura S., Weidmann E., Hirabayashi H., Johnson J. T., Herberman R. B., Whiteside T. L. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck. Int J Cancer. 1994 May 1;57(3):297–305. doi: 10.1002/ijc.2910570302. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES